Software for the objective testing of ADHD.

This is a Provider Selection Regime (PSR) confirmation of contract award notice. This contract has been awarded under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.

This is a Provider Selection Regime (PSR) confirmation of contract award notice. This contract has been awarded under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. This is for the provision of QbTest. Qb Test is an ADHD testing software that enables clinical teams to measure the 3 main symptom domains of ADHD and compare the results to an age and gender matched control group. QbTest can be used for patients aged 6 to 60 years old. Results are presented in a visual report. Award has been made following PSR Direct Award Process A. The estimated lifetime value of the Contract: £37,440.00 Provision is to be provided: 1st September 2026 – 31st August 2028, with option to extend up to 12 months. Decision makers include the service manager and finance business partner.

Public Contracts Regulations 2015 (Directive 2014/24/EU)

Award procedure without prior publication of a call for competition Qbtech Ltd is the sole provider of QbCheck, the only FDA Cleared, EMA registered and CE Marked online medical device available in the UK to objectively measure Hyperactivity, Inattention and Impulsivity. QbCheck is cleared for use as an aid in the assessment and treatment evaluation of ADHD for those aged 6-60 years old. Details of the FDA Clearances are: To aid in the clinical assessment of ADHD in children (K040894); To aid in the clinical assessment of ADHD in adolescents and adults (K122149); and: To aid in the evaluation of treatment interventions in patients with ADHD (K133382).

Lot 1: Bids: 1